SCHEMBL731242

SCHEMBL731242

COc1ccc(OC(N)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.61
CA2 P00918 5/20 0.61
PARP10 Q53GL7 2/20 0.61
PARP1 P09874 1/20 0.61
PARP2 Q9UGN5 1/20 0.61
PARP4 Q9UKK3 1/20 0.61
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
CA12 O43570 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
PRSS1 P07477 2/20 0.51
ACR P10323 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
KIF11 P52732 1/20 0.50
PRSS2 P07478 1/20 0.50
PRSS3 P35030 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28845837 0.94 PARP10 (0.66) CA1CA2PARP10PARP1PARP2
SCHEMBL27596967 0.94 KIF11 (0.59) CA1CA2PARP10PARP1PARP2
SCHEMBL3964510 0.88 F3 (0.50) CA1CA2PARP10PARP1PARP2
SCHEMBL6284986 0.87 KMT2A (0.64) CA1CA2PARP10PARP1PARP2
SCHEMBL28304654 0.84 L3MBTL1 (0.62) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
Hydrochloric Acid SCHEMBL10436132 0.82 L3MBTL1 (0.60) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL28213866 0.82 CA1 (0.57) CA1CA2PARP10PARP1PARP2
SCHEMBL473211 0.81 LMNA (0.64) CA1CA2PARP10CA9MEN1
SCHEMBL7061292 0.80 CES2 (0.58) CA1CA2PARP10PARP1PARP2
SCHEMBL1398350 0.80 CES2 (0.58) CA1CA2PARP10PARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113214339-A Panaxadiol derivatives, preparation method and medical application thereof 延边大学 2021-08-06 CN claimed
CN-108864127-B Oxidobicycloheptene sulfonamide compound with different alkyl chain lengths as well as preparation method and application thereof 武汉大学 2020-06-23 CN claimed
CN-106046100-A 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases 拜耳知识产权有限责任公司 2016-10-26 CN claimed
US-20260034228-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE SDG LLC (US) 2026-02-05 US disclosed
US-12377154-B2 Drug delivery system for treating disease SDG, LLC (US) 2025-08-05 US disclosed
WO-2024062843-A1 COLORED COMPOSITION, COLORED PRODUCT, AND COMPOUND 富士フイルム株式会社 2024-03-28 WO disclosed
WO-2024024438-A1 CLATHRATE COMPOUND AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED PRODUCT, AND LAMINATE 富士フイルム株式会社 2024-02-01 WO disclosed
WO-2024004793-A1 COMPOUND, COMPOSITION, FILM, METHOD FOR PRODUCING COLORED COMPOSITION, AND METHOD FOR PRODUCING LAMINATE FOR DISPLAY ELEMENT 富士フイルム株式会社 2024-01-04 WO disclosed
WO-2024004492-A1 PHOTOSENSITIVE COMPOSITION, TRANSFER FILM, LAMINATE, AND METHOD FOR MANUFACTURING SAME, AND MICRO LED DISPLAY 富士フイルム株式会社 2024-01-04 WO disclosed
US-20230381326-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE SDG, LLC 2023-11-30 US disclosed
WO-2023190070-A1 COMPOUND, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED PRODUCT, AND LAMINATE 富士フイルム株式会社 2023-10-05 WO disclosed
EP-0556700-A1 Silver halide color photosensitive material FUJI PHOTO FILM CO., LTD. (JP) 1993-08-25 EP disclosed
EP-0545420-A2 Imidazole azo dyes and thermal transfer dye donating materials containing them FUJI PHOTO FILM CO., LTD. (JP) 1993-06-09 EP disclosed
EP-0518238-A1 Pyrrolotriazole derivative FUJI PHOTO FILM CO., LTD. (JP) 1992-12-16 EP disclosed
EP-0244160-B1 LIGHT-SENSITIVE SILVER HALIDE PHOTOGRAPHIC MATERIAL IMPROVED IN STABILITY OF DYE IMAGE KONICA CORPORATION (JP) 1990-10-17 EP disclosed
US-4914206-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-04-03 US disclosed
EP-0296811-A3 CARBAMATES OF 4-HYDROXYANISOLE AS PRODRUGS FOR CHEMOTHERAPY OF MELANOMA MERCK & CO. INC. (US) 1990-03-21 EP disclosed
US-4812590-A Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma MERCK & CO., INC. (US) 1989-03-14 US disclosed
EP-0296811-A2 Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma MERCK & CO. INC. (US) 1988-12-28 EP disclosed
EP-0226896-A2 Lankacidin derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034228-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE HM13, HCAR2, HBZ CA1 713/4885CA2 663/4885PARP10 2569/4885
US-12377154-B2 Drug delivery system for treating disease HPGDS, VHL, HPSE CA1 1007/4885CA2 636/4885PARP10 4288/4885
US-20230381326-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE HPGDS, VHL, HPSE CA1 1007/4885CA2 636/4885PARP10 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.